Data compiled by Redley Lamar · ChainSifter Intelligence
5Suppliers
9Customers
3Debt Items
20Related Chains
Source-Backed Evidence Depth
Relay Therapeutics, Inc. (RLAY) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
18Total relationships
4Distinct source URLs
13High confidence
0.847Average confidence
2026-10-28Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Relay Therapeutics, Inc. Suppliers
Ticker
Name
Confidence
Evidence
JEFFERIES-LLC
JEFFERIES-LLC
92%
Relay Therapeutics, Inc. entered into an Underwriting Agreement with Jefferies LLC and TD Securities (USA) LLC, as representatives of the several underwriters listed on Schedule 1 thereto
TD-SECURITIES-USA-LLC
TD-SECURITIES-USA-LLC
92%
Relay Therapeutics, Inc. entered into an Underwriting Agreement with Jefferies LLC and TD Securities (USA) LLC, as representatives of the several underwriters listed on Schedule 1 thereto
D-E-SHAW-RESEARCH-LLC
D-E-SHAW-RESEARCH-LLC
90%
Under the DESRES Agreement, we agreed to collaborate with D. E. Shaw Research to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused…
Reciprocal relationship from PVLA graph: ion, future events, or otherwise, except as may be required by law. SUMMARY OF PRINCIPAL RISK FACTORS Below is a summary of material factors that make an inve…
Reciprocal relationship from RVMDW graph: Reciprocal relationship from RLAY graph: Reciprocal relationship from RVMDW graph: Reciprocal relationship from RLAY graph: Reciprocal relationship from RVMD…
Relay Therapeutics, Inc. Customers
Ticker
Name
Confidence
Evidence
ELEVAR
ELEVAR
92%
Pursuant to the Elevar Agreement, Elevar was granted global development and commercialization rights for lirafugratinib.
Reciprocal relationship from PFE graph: Reciprocal relationship from RLAY graph: Braftovi (encorafenib), a BRAF inhibitor indicated for use in combination with Mektovi (binimetinib), a MEK inhibitor,…
Braftovi (encorafenib), a BRAF inhibitor indicated for use in combination with Mektovi (binimetinib), a MEK inhibitor, both marketed by Pfizer for the treatment of metastatic melanoma with a BRAF V60…
ELEVAR-AGREEMENT
ELEVAR-AGREEMENT
90%
During the three months ended March 31, 2026, the Company recognized $3.0 million of revenue from the Elevar Agreement, specifically upon receipt of certain milestone payments.
GENENTECH
GENENTECH
90%
Under the terms of the Genentech Agreement, we received $75.0 million in an upfront payment in 2021, as well as $45.0 million in milestone payments from Genentech as of December 31, 2024.
ELEVAR-THERAPEUTICS-INC
ELEVAR-THERAPEUTICS-INC
85%
ctively. Elevar Therapeutics, Inc. In December 2024, the Company and Elevar Therapeutics, Inc. ("Elevar") entered into the Exclusive License Agreement ("Elevar Agreement"), pursuant to which Elevar w…
Reciprocal relationship from PVLA graph: Reciprocal relationship from RLAY graph: Reciprocal relationship from PVLA graph: Reciprocal relationship from RLAY graph: Reciprocal relationship from PVLA g…
Reciprocal relationship from RVMDW graph: o the type, complexity and novelty of the program, and often can be several years or more per program. Delays associated with programs for which we are direc…
D-E-SHAW-RESEARCH-LLC
D-E-SHAW-RESEARCH-LLC
62%
ctively. Elevar Therapeutics, Inc. In December 2024, the Company and Elevar Therapeutics, Inc. ("Elevar") entered into the Exclusive License Agreement ("Elevar Agreement"), pursuant to which Elevar w…
Relay Therapeutics, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
RLAY-DEBT-12216
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2020-12-31.
RLAY-DEBT-12215
Warrants outstanding: 2836000
90%
xbrl warrant detail from xbrl 2021-12-31.
RLAY-DEBT
Debt stack $31.6M
90%
Market cache reports total debt of $31.6M.
Relay Therapeutics, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Relay Therapeutics, Inc..
Relay Therapeutics, Inc. Ownership
Holder
Name
Confidence
Evidence
RLAY-OWNER-SB-INVESTMENT-ADVISERS-UK-LTD
SB INVESTMENT ADVISERS (UK) LTD
90%
13F overlay lists SB INVESTMENT ADVISERS (UK) LTD as top holder; 244 tracked holders.
Relay Therapeutics, Inc. Extended Supply Chain Network
